Please login to the form below

Not currently logged in
Email:
Password:

Idera Pharmaceuticals names new CEO

Vincent Milano was most recently CEO of Viropharma

Vincent Milano has been appointed CEO of Idera Pharmaceuticals almost one year after stepping down as CEO of ViroPharma.

Milano left rare disease specialist ViroPharma in January 2014 shortly after the company was acquired by Shire Pharmaceuticals.

He now takes charge of Idera, a clinical-stage biopharmaceutical company that also has an interest in rare diseases.

Jim Geraghty, chairman of Idera, commented on Milano's success at ViroPharma: “Vin is an experienced biopharmaceutical executive with a proven track record of value creation, who led ViroPharma to become a widely admired company successfully delivering innovative treatments to patients with serious unmet medical needs."

Milano succeeds Sudhir Agrawal, who will remain at Idera as president of research and will serve on the company's board of directors.

“As a co-founding scientist and a pioneer in the field of nucleic acid therapeutics, he will continue to lead scientific research for the company,” said Geraghty.

Milano spent nearly 20 years at ViroPharma serving as chief financial officer from 1997 to 2006 when he was named CEO. His previous experience includes a senior manager role at accounting firm KPMG.

5th December 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics